Stopoutsin (Stoptussin)

Composition Pharmacodynamics Indications Carefully Contraindications Dosing and Administration Side effects Form release / dosage
Read on
Active substanceButamyrate + GuaifenesinButamyrate + Guaifenesin
Similar drugsTo uncover
  • Stopoutsin
    drops inwards 
    Teva Pharmaceutical Enterprises Co., Ltd.     Israel
    • Dosage form: & nbspDrops for oral administration.
    Composition:1 ml of the drug contains
    Active substances: Guaifenesin 0.100 g, butylate citrate 0.004 g
    Excipients: ethanol 96% 0.300 g, floral flavor (aroma of alpine flowers) 0.002 g, purified water 0.007 g, polysorbate-80 0.001 g, licorice extract, liquid 0.003 g, propylene glycol up to 1,000 ml.
    Description:
    Transparent viscous liquid from yellow to yellowish brown color.

    Pharmacotherapeutic group:Antitussive + expectorant.
    ATX: & nbsp
  • Other antimicrobials
    • Pharmacodynamics:
    Combined drug, which has antitussive and expectorant effect. Butamirate dihydrogen citrate has a peripheral local anesthetic effect on the sensitive nerve endings of the bronchial mucosa, which provides an antitussive effect.

    Guaifenesin increases the secretion of bronchial glands and reduces the viscosity of mucus. Increased secretion is caused as a direct effect on the bronchial glands by stimulating the secretion of secretions from the bronchial glands and removing acidic glycoproteins from acinar cells and reflexively when irritation of the afferent parasympathetic fibers of the gastric mucosa occurs and the respiratory center is depressed. Increase of tone N.vagus stimulates the production of bronchial secretions. Slime produced by the bronchial glands enhances the activity of the ciliary epithelium, which facilitates the evacuation of mucus from the bronchi and its coughing.
    Pharmacokinetics:When administered butramate citrate quickly and completely absorbed. The connection with plasma proteins is 94%. It is metabolized with the formation of 2 metabolites, which also have antitussive action. Metabolites are excreted mainly (90%) by the kidneys and only a small part through the intestine. The half-life (T1 / 2) -6 hours. Guaifenesin when administered inside quickly absorbed from the gastrointestinal tract. The connection with plasma proteins is insignificant. Guaifenesin rapidly metabolized, with the formation of inactive metabolites, which are excreted by the kidneys. T1 / 2-1h.
    Indications:
    - Dry cough and irritating cough of various etiologies (including infectious and inflammatory diseases of the upper and lower respiratory tract).

    - Cough relief in the pre- and postoperative period
    Contraindications:
    - Hypersensitivity to the constituent components;

    - myasthenia gravis;

    - children's age up to 6 months;

    - the first trimester of pregnancy;

    - the period of lactation.
    Pregnancy and lactation:STOPTUSSIN should not be given in the first trimester of pregnancy, but for particularly later periods of pregnancy, especially important reasons should be used. It is not known whether butamate citrate and guaifenesin in mother's milk. Therefore, for the use of the drug STOPTUSSIN during breastfeeding, it is necessary to evaluate the ratio of the benefits of treatment for the mother and the possible risk to the baby.
    Dosing and Administration:
    The drug is taken after a meal, the appropriate number of drops are dissolved in 100 ml of liquid (water, tea, fruit juice, etc.). If a syringe is added to the drug for dosing, you can use it to accurately dial the drug.

    Dosed depending on the patient's body weight:

    up to 7 kg - 8 drops 3-4 times a day,

    7-12 kg - 9 drops 3-4 times a day,

    12-20 kg - 14 drops 3 times a day,

    20-30 kg - 14 drops 3-4 times a day,

    30-40 kg - 16 drops 3-4 times a day,

    40-50 kg - 25 drops 3 times a day,

    50-70 kg - 30 drops 3 times a day,

    more than 70 kg - 40 drops 3 times a day.

    The interval between doses should be 6-8 hours.

    The use of a large amount of fluid during the course of treatment enhances its effectiveness.When used in children weighing less than 7 kg, a dose reduction is possible, due to the fact that the child does not drink all 100 ml of the prepared mixture, however, the total concentration of the preparation should not be exceeded.

    In the absence of a positive effect, you should see a doctor.

    INSTRUCTION FOR USE OF SYRINGE FOR DOSING

    For simple and accurate dosing of the drug, you can use a syringe for dosing (if attached) (Fig. 1).


    The scale on the syringe shows the number of drops in the metered dose.

    1. Unscrew the bottle cap (counter-clockwise).

    2. Place the syringe in the adapter on the neck of the bottle in an upright position (Fig. 2).



    3. The bottle with the syringe placed in it should be turned upside down. Hold the syringe tightly and, pulling the piston, dial the required amount of the drug (Fig. 3).

    .

    If you want to measure a dose of 40 drops - dial 10 + 30 drops.

    5. Turn the bottle back to the upright position.

    6. Carefully pull out the syringe with the drug from the bottle adapter.

    7. Dissolve the dosed preparation in water, tea or fruit juice.

    8. Screw the bottle with the preparation (clockwise).

    9. After use, rinse the syringe with warm water.


    Side effects:

    When the recommended dosage regimen is observed, patients usually tolerate the drug well. Nausea, vomiting, diarrhea, decreased appetite, stomach pain, dizziness, headache, drowsiness, hives, and skin rashes may occur. These effects appear in about 1% of patients and usually go without reducing the dose. The frequency of adverse reactions listed below was determined according to the following criteria: very often (not less than 1/10), often (more than 1/100, less than 1/10); sometimes (more than 1/1000, less than 1/100); rarely (more than 1/10000, less than 1/1000); very rarely (less than 1/10000), including individual messages.

    From the nervous system: often - anorexia, headache.

    From the organs of hearing and balance: often - dizziness.

    On the part of the digestive system: often g, nausea, abdominal pain, vomiting, diarrhea.

    From the skin and subcutaneous fat: very rarely - exanthema, urticaria.

    From the side of the kidneys and urinary tract: very rarely - urolithiasis.

    Overdose:
    Symptoms: Overdose is dominated by signs of toxic effects of guaifenesin: drowsiness, muscle weakness, nausea and vomiting, urolithiasis.
    Treatment: In case of overdose, see a doctor. Guaifenesin does not have a specific antidote.Assign gastric lavage, reception of activated charcoal, symptomatic therapy (support of cardiovascular, respiratory and renal functions, electrolyte balance).
    Interaction:
    Guaifenesin enhances the analgesic effect of paracetamol and acetylsalicylic acid; enhances the effect of alcohol, sedatives, hypnotics and general anesthetics on the central nervous system; action of muscle relaxants.

    When determining the concentration of vanillylmindal and 5-hydroxyindoleacetic acid using nitrosoftoft as a reagent, false positive results can be obtained. Therefore, treatment with guaifenesin should be stopped 48 hours before urine collection for this analysis.
    Special instructions:
    If symptoms persist, consider changing the treatment.

    The preparation contains 36.6% by volume of ethanol. Avoiding alcoholic beverages during the course of treatment should be avoided. The drug should not be administered with productive cough to patients suffering from prolonged or chronic coughing (including those caused by smoking), bronchitis or emphysema of the lungs.
    Effect on the ability to drive transp. cf. and fur:The use of the drug may have an adverse effect on activities requiring increased attention, coordination of movements and rapid decision-making (for example, driving, working with machinery and high-altitude work).
    Form release / dosage:Drops for oral administration.
    Packaging:
    To 10, 25 and 50 ml in bottles of dark glass with a polyethylene dropper, cover with the control of opening.

    To 50 ml in bottles of dark glass with polyethylene dropper, cover with tamper control and polyethylene syringe for dosing. Each bottle is placed in a cardboard box along with the instructions for use.
    Storage conditions:The drug should be stored at a temperature of 10 ° C to 25 ° C, protected from light and out of the reach of children.
    Shelf life:5 years! Do not use after the date indicated on the package.
    Terms of leave from pharmacies:Without recipe
    Registration number:П N012577 / 01
    Date of registration:02.06.2011
    The owner of the registration certificate:Teva Pharmaceutical Enterprises Co., Ltd.Teva Pharmaceutical Enterprises Co., Ltd. Israel
    Manufacturer: & nbsp
    Representation: & nbspTeva Teva Israel
    Information update date: & nbsp31.03.2016
    Illustrated instructions
    Instructions
    Up